Active autoimmune disease, symptomatic interstitial lung disease, systemic immunosuppression; with EGFR-mutation-positive tumors or known ALK receptor tyrosine kinase (ALK) translocation-positive tumors; prior treatment with an EGFR, anaplastic lymphoma kinase inhibitor, anti-tumor vaccine, immunostimulatory antitumor agent, immune checkpoint inhibitor, or docetaxel. This evidence concerns the gene ALK and autoimmune disease.